EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Role of Neutrophil Lymphocyte Ratio (NLR) in Predicting Disease Severity in Covid -19

Khadija ASİF, Farhat ABBAS

Turkish Journal of Internal Medicine · 2022

DOI: 10.46310/tjim.1011041 ↗
AbstractBibliografische Angaben

Abstract

Background: To evaluate the role of NLR as a prognostic indicator for severe COVID-19, due to its positive correlation with disease severity, easy accessibility and low cost. Material and Methods: A multicenter retrospective observational study was conducted in COVID-19 wards of two tertiary care hospitals of Faisalabad city, Pakistan, treating COVID-19 patients between May 2021 - July 2021. A predesigned proforma was filled to collect the data. SPSS 21 was used for the statistical analysis of this research. Results: A record of 100 COVID-19 patients admitted between May 2021 - July 2021, fulfilling the inclusion criteria was included in the study. All patients were divided into two groups. The non-severe group included 37 patients while the severe group included 63 patients. The mean age of the study population was 56 years with male predominance (63%). Overall, 50% of patients in the non-severe group and 71% in the severe group had some co-existent comorbidity. Fever and cough were the most commonly reported symptoms in both groups while shortness of breath was more widely reported in the severe group (74.2%). The mean NLR in the non-severe group was 4 as compared to 12 in the severe group. Conclusions: Higher neutrophil lymphocyte ratio (NLR) is associated with severe COVID -19 and can be used as an effective tool to predict the progression of the non-severe disease to severe disease.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →